Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine
The Journal of Pediatrics, ISSN: 0022-3476, Vol: 124, Issue: 6, Page: 921-926
1994
- 35Citations
- 18Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations35
- Citation Indexes33
- 33
- CrossRef26
- Policy Citations2
- Policy Citation2
- Captures18
- Readers18
- 12
Article Description
The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-linked immunosorbent assay titers to pertussis toxin, filamentous hemagglutinin, and pertactin, as well as the pertussis toxin-neutralizing titer measured by the Chinese hamster ovary cell assay, were significantly higher after the acellular vaccine was given. Both vaccines induced adequate levels of anti-diphtheria and anti-tetanus antibodies. We conclude that the recombinant acellular pertussis vaccine produces fewer reactions than the whole-cell vaccine and provides a high antibody response against the antigens of Bordetella pertussis involved in bacterial adhesion and systemic toxic effects.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022347605831816; http://dx.doi.org/10.1016/s0022-3476(05)83181-6; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0028232732&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/8201477; https://linkinghub.elsevier.com/retrieve/pii/S0022347605831816; http://linkinghub.elsevier.com/retrieve/pii/S0022347605831816; http://api.elsevier.com/content/article/PII:S0022347605831816?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0022347605831816?httpAccept=text/plain
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know